Universitätsklinikum Jena

The eha research roadmap: Infections in hematology (2021) Cordonnier C, Ljungman P, Cesaro S, Hirsch HH, Maschmeyer G, Von Lilienfeld-Toal M, Vehreschild M, et al. Journal article, Review article Correlation of crystal violet biofilm test results of Staphylococcus aureus clinical isolates with Raman spectroscopic read-out (2021) Ebert C, Tuchscherr L, Unger N, Poellath C, Gladigau F, Popp J, Loeffler B, Neugebauer U Journal article Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance (2021) Schumann T, König J, von Loeffelholz C, Vatner DF, Zhang D, Perry RJ, Bernier M, et al. Journal article An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer (2021) Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, et al. Journal article Environmental signals rather than layered ontogeny imprint the function of type 2 conventional dendritic cells in young and adult mice (2021) Papaioannou NE, Salei N, Rambichler S, Ravi K, Popovic J, Küntzel V, Lehmann C, et al. Journal article Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4 (2021) Kayser S, Martinez-Cuadron D, Hanoun M, Stoelzel F, Gil C, Reinhardt HC, Aguiar E, et al. Conference contribution Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia (2021) Rautenberg C, Stoelzel F, Roellig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, et al. Conference contribution Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis (2021) Dreger P, Schubert ML, Holtick U, Subklewe M, Von Bastian T, Ayuk FA, Wagner EM, et al. Conference contribution Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis (2021) Bethge WA, Martus P, Schmitt M, Holtick U, Borchmann P, Subklewe M, Rejeski K, et al. Conference contribution Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute BLymphoblastic Leukemia (INITIAL-1 trial) (2021) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution